Trendlines sells BioSight for US$1.3 mil

SINGAPORE (June 6): Trendlines Group, the investor, incubator and developer of early-stage, high-promise medical and agricultural technology companies, has signed an agreement for the sale of BioSight to Arkin Bio Ventures.

The group is expected to gain pretax net proceeds of about US$1.3 million ($1.8 million) – about US$1 million after tax – upon completing the transaction, which is expected to take place within 14 business from signing the agreement.

Trendlines says BioSight was acquired for next to nothing in 2007 as a part of Trendlines Medical-Misgav, now named Trendlines Incubators Israel.

---

Related Stories

• Trendlines expects US$25 mil to US$30 mil loss for FY2023 in profit warning
• Trendlines is impacted by Hamas invasion, company says
• Trendlines to report a loss for 1HFY2022 with US$7.9 mil portfolio company write-off

---